A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

TY - JOUR

T1 - A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

AU - Kyhl, Kasper

AU - Lønborg, Jacob

AU - Vejlstrup, Niels

AU - Kelbæk, Henning

AU - Helqvist, Steffen

AU - Holmvang, Lene

AU - Jørgensen, Erik

AU - Saunamäki, Kari

AU - Bøtker, Hans Erik

AU - Clemmensen, Peter

AU - Køber, Lars

AU - Treiman, Marek

AU - Engstrøm, Thomas

PY - 2016/7/20

Y1 - 2016/7/20

N2 - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

AB - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

KW - Journal Article

U2 - 10.4244/eijv12i4a78

DO - 10.4244/eijv12i4a78

M3 - Journal article

C2 - 27436599

SN - 1774-024X

VL - 12

SP - 449

EP - 455

JO - EuroIntervention

JF - EuroIntervention

IS - 4

ER -